EGFR+ Lung Cancer

Liquid biopsies have evolved beyond finding genotypes and have moved into the cancer detection and monitoring spaces, according to Geoffrey R. Oxnard, MD, medical oncologist at the Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School.

Rogerio Lilenbaum, MD,&nbsp;highlights the current treatment approaches for patients with <em>EGFR</em>-positive NSCLC and sheds light on the potential for immunotherapy in the space.

Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.

A look back at all the&nbsp;FDA news&nbsp;in oncology from the month of&nbsp;January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.

Based on data from the&nbsp;phase III KEYNOTE-189 trial, the FDA has expanded the approval for&nbsp;pemetrexed injection in combination with pembrolizumab and platinum-based chemotherapy to include the first-line treatment of patients with metastatic nonsquamous non&ndash;small cell lung cancer without <em>EGFR</em> or <em>ALK</em> alterations.

During a presentation at the <em>16th Annual </em>Winter Lung Cancer Conference,&nbsp;Julie R. Brahmer, MD, MSc shed light on some of the immunotherapy treatment options that could be entering the lung cancer pipeline over the next 5 years.

Edward B. Garon, MD,&nbsp;discusses the newer role of immunotherapy in the treatment of patients with unresectable stage III NSCLC with the approval of durvalumab in this setting for patients whose disease has not progressed following concurrent chemoradiation.

Christina S. Baik, MD, MPH,&nbsp;discusses several existing and emerging treatment options for <em>ROS1</em>, <em>BRAF</em>, and <em>NTRK </em>genetic aberrations.

During a presentation at the 16th Annual Winter Lung Conference, Gregory J. Riely, MD, PhD, discusses how oncologists can differentiate between the&nbsp;many EGFR TKIs available for patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer.

General Cancer

Bristol-Myers Squibb has announced its decision to withdraw a&nbsp;supplemental biologics license application currently with&nbsp;the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non&ndash;small cell lung cancer with tumor mutational burden &ge;10 mutations per megabase.